Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin†

Michelle Martinot‐Peignoux; Christiane Stern; Sarah Maylin; Marie‐Pierre Ripault; Nathalie Boyer; Laurence Leclere; Corinne Castelnau; Nathalie Giuily; Ahmed El Ray; Ana‐Carolina Cardoso; Rami Moucari; Tarik Asselah; Patrick Marcellin

doi:10.1002/hep.23444

journal article Apr 01, 2010

Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin†

Michelle Martinot‐Peignoux Christiane Stern Sarah Maylin

Marie‐Pierre Ripault Nathalie Boyer Laurence Leclere Corinne Castelnau Nathalie Giuily Ahmed El Ray Ana‐Carolina Cardoso Rami Moucari Tarik Asselah

Patrick Marcellin

Hepatology Vol. 51 No. 4 pp. 1122-1126 · Ovid Technologies (Wolters Kluwer Health)

View at Publisher Save 10.1002/hep.23444

Topics

No keywords indexed for this article. Browse by subject →

References

26

[1]

Marcellin "Long‐term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon‐alpha therapy" Ann Intern Med (1997) 10.7326/0003-4819-127-10-199711150-00003

[2]

Lau "10‐Year follow‐up after interferon‐alpha therapy for chronic hepatitis C" HEPATOLOGY (1998) 10.1002/hep.510280430

[3]

Maylin "Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C" Gastroenterology (2008) 10.1053/j.gastro.2008.05.044

[4]

George "Clinical, virologic, histologic and biochemical outcomes after successful HCV therapy: a 5‐year follow‐up of 150 patients" HEPATOLOGY (2009) 10.1002/hep.22694

[5]

Poynard "Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus" Lancet (1998) 10.1016/s0140-6736(98)07124-4

[6]

McHutchison "Interferon alfa‐2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C" N Engl J Med (1998) 10.1056/nejm199811193392101

[7]

Zeuzem "Peginterferon alfa‐2a in patients with chronic hepatitis C" N Engl J Med (2000) 10.1056/nejm200012073432301

[8]

Heathcote "Peginterferon alfa‐2a in patients with chronic hepatitis C and cirrhosis" N Engl J Med (2000) 10.1056/nejm200012073432302

[9]

Lindsay "A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C" HEPATOLOGY (2001) 10.1053/jhep.2001.26371

[10]

Manns "Peginterferon alfa‐2b plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial" Lancet (2001) 10.1016/s0140-6736(01)06102-5

[11]

Fried "Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection" N Engl J Med (2002) 10.1056/nejmoa020047

[12]

Hadziyannis "Peginterferon‐a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose" Ann Intern Med (2004) 10.7326/0003-4819-140-5-200403020-00010

[13]

Reichard "Long‐term follow‐up of chronic hepatitis C patients with sustained virological response to alpha‐interferon" J Hepatol (1999) 10.1016/s0168-8278(99)80129-9

[14]

McHutchison "Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin" HEPATOLOGY (2002) 10.1053/jhep.2002.31870

[15]

Veldt "Long term clinical outcome of chronic hepatitis C patients with sustained virologic response to interferon monotherapy" Gut (2004) 10.1136/gut.2003.038257

[16]

Sarazin "Detection of residual hepatitis C virus RNA by transcription‐mediated amplification in patients with complete virologic response according to polymerase chain reaction‐based assays" HEPATOLOGY (2000) 10.1053/jhep.2000.17709

[17]

Gerotto "Hepatitis C minimal residual viremia (MRV) detected by TMA art the end of pegylated‐interferon plus ribavirin therapy predicts post‐treatment relapse" J Hepatol (2006) 10.1016/j.jhep.2005.08.016

[18]

Morishima "Interpretation of positive transcription‐mediated amplification test results from polymerase chain reaction‐negative samples obtained after treatment for chronic hepatitis C" HEPATOLOGY (2008) 10.1002/hep.22487

[19]

Comanor "Transcription‐mediated amplification is more sensitive than conventional PCR‐based assays for detecting residual serum HCV‐RNA at end of treatment" Am J Gastroenterol (2001) 10.1111/j.1572-0241.2001.04669.x

[20]

Elbeik "Multicenter evaluation of the performance characteristics of the Bayer VERSANT HCV‐RNA 3.0 assay (bDNA)" J Clin Microbiol (2004) 10.1128/jcm.42.2.563-569.2004

[21]

Zeuzem "Twelve weeks follow‐up is sufficient for the deternination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C" J Hepatol (2003) 10.1016/s0168-8278(03)00187-9

[22]

Martinot‐Peignoux "Pretreatment serum HCV‐RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C" HEPATOLOGY (1995) 10.1002/hep.1840220406

[23]

Martinot‐Peignoux "Predictors of sustained response to alpha interferon therapy in chronic hepatitis C" J Hepatol (1998) 10.1016/s0168-8278(98)80006-8

[24]

Berg "Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy" HEPATOLOGY (2003) 10.1053/jhep.2003.50106

[25]

Martinot‐Peignoux "Accurate models predicting sustained response with pegylated interferon with ribavirin in patients with chronic hepatitis C" J Viral Hepatitis (2006) 10.1111/j.1365-2893.2006.00750.x

[26]

Martinot‐Peignoux "Virologic response at 4 weeks to predict outcome of hepatitis C treatment with peginterferon and ribavirin" Antivir Ther (2009) 10.1177/135965350901400403

Metrics

135

Citations

26

References

Details

Published: Apr 01, 2010
Vol/Issue: 51(4)
Pages: 1122-1126
License: View

Authors

M

Michelle Martinot‐Peignoux

APHP, Microbiology laboratory; Hôpital Saint-Louis; Paris France

Cite This Article

Michelle Martinot‐Peignoux, Christiane Stern, Sarah Maylin, et al. (2010). Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin†. Hepatology, 51(4), 1122-1126. https://doi.org/10.1002/hep.23444

Twelve weeks posttreatment follow‐up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin†

You May Also Like